Tactile Medical/$TCMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tactile Medical
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
- Ticker
- $TCMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,086
- Headquarters
- Minneapolis, United States
- Website
- tactilemedical.com
Tactile Medical Metrics
BasicAdvanced
$522M
21.32
$1.08
0.82
-
Price and volume
Market cap
$522M
Beta
0.82
52-week high
$37.77
52-week low
$14.84
Average daily volume
199K
Financial strength
Current ratio
4.12
Quick ratio
3.368
Long term debt to equity
0.05
Total debt to equity
0.064
Interest coverage (TTM)
139.56%
Profitability
EBITDA (TTM)
41.738
Gross margin (TTM)
76.78%
Net profit margin (TTM)
7.10%
Operating margin (TTM)
10.00%
Effective tax rate (TTM)
33.44%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
7.92%
Return on equity (TTM)
11.88%
Valuation
Price to earnings (TTM)
21.32
Price to revenue (TTM)
1.479
Price to book
2.34
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
21.888
Free cash flow yield (TTM)
4.57%
Free cash flow per share (TTM)
1.053
Growth
Revenue change (TTM)
17.22%
Earnings per share change (TTM)
72.86%
3-year revenue growth (CAGR)
9.56%
10-year revenue growth (CAGR)
17.24%
3-year earnings per share growth (CAGR)
328.45%
10-year earnings per share growth (CAGR)
33.09%
What the Analysts think about Tactile Medical
Analyst ratings (Buy, Hold, Sell) for Tactile Medical stock.
Analyst projections of the future price of Tactile Medical stock.
Bulls say / Bears say
Lymphedema is driving solid growth: second-quarter revenue rose 12%, and total company revenue increased 9%. Management expects low-double-digit lymphedema growth for 2026, supporting a continuing core growth engine. (Tactile Medical)
Profitability improved sharply in the second quarter: net income more than doubled to $7.8 million and adjusted EBITDA rose 49% to $11.4 million, with gross margin expanding to 76%. The company also had $69.9 million in cash and no borrowings, giving it room to fund growth. (Tactile Medical)
Clinical evidence may widen Flexitouch’s use: a 236-patient trial found patient-reported outcomes comparable with therapist-guided care for head and neck cancer-related lymphedema. The findings could help Tactile build clinician awareness and seek broader payer coverage. (The Motley Fool)
Airway-clearance sales fell 7% in the second quarter as large equipment distributors worked through elevated AffloVest inventory. Tactile lowered its revenue outlook range and now expects this business to be roughly flat for 2026, making results dependent on inventory normalising. (Tactile Medical)
New Medicare prior-authorisation rules added steps to the ordering process and moderated Medicare order volumes in the second quarter. Longer approval and shipment processes could delay or prevent sales in an important customer channel. (The Motley Fool)
Operating costs are a risk to earnings: first-quarter operating expenses rose 19% year on year and the company recorded a $1.5 million operating loss. Continued investment in sales and technology will need to translate into revenue growth to sustain profitability. (Tactile Medical)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
Tactile Medical Financial Performance
Revenues and expenses
Tactile Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tactile Medical News
AllArticlesVideos
Funds containing Tactile Medical
Fund name | Fund size | $TCMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.